Megestrol Acetate for Prevention of Weight Loss During Modern Radiotherapy in Patients With Head and Neck Cancer: A Multicenter Randomized Controlled Trial.
Muangwong Pooriwat P, Samakgarn Vatanyu V, Malasri Panlop P, Toapichattrakul Piyapasara P et al.
Weight loss is a common complication during radiotherapy for head and neck cancer and may adversely affect treatment tolerance and outcomes. We evaluated whether megestrol acetate (MA) prevents treatment-related weight loss. In this multicenter, open-label randomized controlled trial, 102 patients with non-nasopharyngeal head and neck squamous cell carcinoma undergoing radiotherapy were assigned to MA plus standard care or standard care alone. Standard care consisted of nutritional counseling, symptom management, and feeding-tube placement when clinically indicated. The primary endpoint was change in body weight from baseline to 6 weeks post-radiotherapy. At 6 weeks post-radiotherapy, the MA group showed a mean weight gain of 2.07 kg, whereas the control group lost 1.74 kg (p < 0.01). Weight gain was primarily due to increased fat mass, with no significant difference in muscle mass. Quality of life was similar between groups. MA improved weight preservation during radiotherapy and may serve as an adjunct to supportive care in head and neck cancer. ClinicalTrials.gov identifier: TCTR20240330005.